Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study This is an ASCO Meeting Abstract ...
Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in ...
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment. Background: Current NCCN guidelines recommend ...
Thirteen patients were treated during study (Table 1). Vaccination was generally well tolerated with the most common toxicity being local induration or erythema at the site of inoculation. Eleven ...
Chronic myeloid leukemia (CML) is characterized by the formation of the Philadelphia chromosome and oncogenic signaling by the resulting Bcr-Abl fusion protein. Understanding the molecular basis of ...
(NASDAQ: ARIA) today announced twelve-month follow-up data from the pivotal PACE trial of , its investigational BCR-ABL inhibitor, in heavily pretreated patients with resistant or refractory chronic ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 90, No. 8 (Apr. 15, 1993), pp. 3755-3759 (5 pages) Lethally irradiated mice reconstituted with bone marrow ...
Terns Pharmaceuticals Inc., a NASH specialist based in San Francisco and Shanghai, has out-licensed the Greater China rights of its BCR-ABL inhibitor, TRN-000632, for treating chronic myeloid leukemia ...
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from ...
SUZHOU, China and ROCKVILLE, Md., Nov. 14, 2019 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, ...
*Patients with at least 6 months follow-up. ‡ Response rate in patients without a CHR at baseline. CCyR = Complete cytogenetic response; CHR = Complete hematologic response; MCyR = Major cytogenetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback